Bank of New York Mellon Corp Purchases 1,205 Shares of Fresenius Medical Care AG (NYSE:FMS)

Bank of New York Mellon Corp raised its holdings in shares of Fresenius Medical Care AG (NYSE:FMS) by 5.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,951 shares of the company’s stock after acquiring an additional 1,205 shares during the quarter. Bank of New York Mellon Corp’s holdings in Fresenius Medical Care were worth $497,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. ABC Arbitrage SA bought a new stake in Fresenius Medical Care during the 4th quarter worth approximately $4,215,000. Quantinno Capital Management LP raised its stake in shares of Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after acquiring an additional 48,554 shares in the last quarter. Franklin Resources Inc. lifted its stake in Fresenius Medical Care by 3.3% in the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock worth $1,490,000 after purchasing an additional 2,386 shares during the last quarter. Crossmark Global Holdings Inc. lifted its stake in shares of Fresenius Medical Care by 2.2% in the 4th quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company’s stock valued at $1,456,000 after acquiring an additional 1,398 shares during the last quarter. Finally, DAVENPORT & Co LLC lifted its position in Fresenius Medical Care by 1.5% in the fourth quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company’s stock valued at $1,316,000 after purchasing an additional 862 shares during the last quarter. 8.37% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on FMS shares. Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Finally, Truist Financial lifted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th.

Fresenius Medical Care Price Performance

Shares of NYSE:FMS opened at $24.58 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The firm has a market cap of $14.42 billion, a price-to-earnings ratio of 20.31, a price-to-earnings-growth ratio of 0.76 and a beta of 0.99. The business has a 50-day simple moving average of $23.99 and a two-hundred day simple moving average of $22.48. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $25.25.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.